Similar BCL-X but different BCL-2 levels in the two age groups of north African nasopharyngeal carcinomas

IARC Working Group on the evaluation of carcinogenic risks to humans. Epstein–Barr virus and Kaposi’s sarcoma Herpesvirus/Human Herpesvirus 8, vol. no. 70. IARC monographs on the evaluation of carcinogenic risks to humans. Lyon, France: IARC; 1997. Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J, editors. Cancer incidence in five continents, vol. VII. IARC Scientific Publications No. 143. Lyon: IARC; 1997. Nicholls, 1997, The association of squamous cell carcinomas of the nasopharynx with Epstein–Barr virus shows geographical variation reminiscent of Burkitt’s lymphoma, J. Pathol., 183, 164, 10.1002/(SICI)1096-9896(199710)183:2<164::AID-PATH919>3.0.CO;2-J Nanbo, 2002, Epstein–Barr virus RNA confers resistance to interferon-alpha-induced apoptosis in Burkitt’s lymphoma, EMBO J., 21, 954, 10.1093/emboj/21.5.954 Tsimbouri, 2002, Bcl-xL and RAG genes are induced and the response to IL-2 enhanced in EμEBNA-1 transgenic mouse lymphocytes, Oncogene, 21, 5182, 10.1038/sj.onc.1205490 Decaussin, 2000, Expression of BARF1 gene encoded by Epstein–Barr virus in nasopharyngeal carcinoma biopsies, Cancer Res., 60, 5584 Gulley, 1998, Nasopharyngeal carcinomas frequently lack the p16/MTS1 tumor suppressor protein but consistently express the retinoblastoma gene product, Am. J. Pathol., 152, 865 Lo, 2001, High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma, Cancer Res., 61, 3877 Effert, 1992, Alterations of the p53 gene in nasopharyngeal carcinoma, J. Virol., 66, 3768, 10.1128/JVI.66.6.3768-3775.1992 Lung ML, Hu Y, Cheng Y, Li MF, Tang CM, Sai-Ki O, Iggo RD. p53 inactivating mutations in Chinese nasopharyngeal carcinomas. Cancer Lett 1998;133:89–94. Sheu, 1997, Analysis of bcl-2 expression in normal, inflamed, dysplastic nasopharyngeal epithelia and nasopharyngeal carcinoma: association with p53 expression, Hum. Pathol., 28, 556, 10.1016/S0046-8177(97)90078-2 Khabir, 2000, Contrasted frequencies of p53 accumulation in the two age groups of north African nasopharyngeal carcinomas, Clin Cancer Res., 6, 3932 Crook, 2000, High level expression of deltaN-p63: a mechanism for the inactivation of p53 in undifferentiated nasopharyngeal carcinoma (NPC)?, Oncogene, 19, 3439, 10.1038/sj.onc.1203656 Ali, 2000, Chemotherapy in advanced nasopharyngeal cancer, Oncology, 14, 1223 Cammoun, 1974, Tumors of the nasopharynx in Tunisia: an anatomic and clinical study based on 143 cases, Cancer, 33, 184, 10.1002/1097-0142(197401)33:1<184::AID-CNCR2820330127>3.0.CO;2-T Stiller, 1994, International variations in the incidence of childhood carcinomas, Cancer Epidemiol. Biomarkers Prev., 3, 305 Sbih-Lammali, 1996, Transcriptional expression of Epstein–Barr virus genes and proto-oncogenes in north African nasopharyngeal carcinoma, J. Med. Virol., 49, 7, 10.1002/(SICI)1096-9071(199605)49:1<7::AID-JMV2>3.0.CO;2-A Lombardi, 1982, Combined radiotherapy and chemotherapy in stages T3 and T4 nasopharyngeal carcinoma in children, Med. Pediatr. Oncol., 10, 243, 10.1002/mpo.2950100304 Mertens, 1997, Nasopharyngeal carcinoma in childhood and adolescence: concept and preliminary results of the cooperative GPOH study NPC-91: Gesellschaft fur Padiatrische Onkologie und Hamatologie, Cancer, 80, 951, 10.1002/(SICI)1097-0142(19970901)80:5<951::AID-CNCR18>3.3.CO;2-N Berberoglu, 2001, Nasopharyngeal carcinoma in Turkish children: review of 33 cases, Pediatr. Hematol. Oncol., 18, 309, 10.1080/088800101300312573 Parkin, 1997, Risk of cancer in migrants and their descendants in Israel. II. Carcinomas and germ-cell tumors, Int. J. Cancer., 70, 654, 10.1002/(SICI)1097-0215(19970317)70:6<654::AID-IJC5>3.0.CO;2-U Cahir-McFarland, 2000, NF-kappa B inhibition causes spontaneous apoptosis in Epstein–Barr virus-transformed lymphoblastoid cells, Proc. Natl. Acad. Sci. U.S.A., 97, 6055, 10.1073/pnas.100119497 D’Souza, 2000, The bfl-1 gene is transcriptionally upregulated by the Epstein–Barr virus LMP1, and its expression promotes the survival of a Burkitt’s lymphoma cell line, J Virol., 74, 6652, 10.1128/JVI.74.14.6652-6658.2000 Lu, 1993, Bcl-2 proto-oncogene expression in Epstein–Barr-virus associated nasopharyngeal carcinoma, Int. J. Cancer, 53, 29, 10.1002/ijc.2910530107 Krajewska M, Krajewski S, Epstein, et al. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol 1996;148:1567–76. Sjostrom, 2002, The predictive value of Bcl-2, Bax, Bcl-xL, Bag-1, Fas, and Fas-L for chemotherapy response in advanced breast cancer, Clin. Cancer Res., 8, 811 Erber, 1997, An enhanced immunocytochemical method for staining bone marrow trephine sections, J. Clin. Pathol., 50, 389, 10.1136/jcp.50.5.389 Pena, 1999, Bcl-X and Bcl-2 expression in squamous cell carcinoma of the head and neck, Cancer, 85, 164, 10.1002/(SICI)1097-0142(19990101)85:1<164::AID-CNCR23>3.0.CO;2-Q Henderson, 1991, Induction of Bcl-2 expression by Epstein–Barr virus latent membrane protein 1 protects infected B-cells from programmed cell death, Cell, 65, 1107, 10.1016/0092-8674(91)90007-L Sheng, 2001, N-terminal domain of BARF1 gene encoded by Epstein–Barr virus is essential for malignant transformation of rodent fibroblasts and activation of BCL-2, Oncogene, 20, 1176, 10.1038/sj.onc.1204217 Maalej, 1995, Clinical and evolutive aspects of nasopharyngeal T4 N0 neoplasms, Bull. Cancer, 82, 728